Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial).
Related Research units
Abstract
To compare the 1-year cost-effectiveness of therapeutic assertive community treatment (ACT) with standard care in schizophrenia. ACT was specifically developed for patients with schizophrenia, delivered by psychosis experts highly trained in respective psychotherapies, and embedded into an integrated care system.
Bibliographical data
| Original language | English |
|---|---|
| Article number | 3 |
| ISSN | 0160-6689 |
| Publication status | Published - 2012 |
| pubmed | 22490266 |
|---|
